viewMotif Bio PLC

Motif Bio passes major landmark as last patient in phase III trial is treated

In all 600 people took part in the REVIVE-1 trial.

Antibiotic resistance means there is a need for a new generation of drugs to treat infection

Motif Bio Plc (LON:MTFB) has passed a major landmark after treating the final patient taking part in the first of two phase III clinical trial of its next-generation antibiotic, iclaprim.

Researchers are using the study to assess the safety and efficacy of the treatment of sufferers of acute bacterial skin and skin structure infections (ABSSSI).

In all 600 people took part in the REVIVE-1 trial. Half were given iclaprim, the remainder received an existing antibiotic called vancomycin.

Only at the end of the antibiotic course will the researchers know which group is which.

The results will be outlined in the second quarter.

The read-out from a second study, REVIVE-2, is expected in the second half.

Successful completion of the two final-stage trials should pave the way for regulatory submissions ahead of the formal green light of the drug in the US and Europe for patients with ABSSSI.

Chief executive Graham Lumsden said: "Thanks to the patients and investigators who participated in REVIVE-1, we remain on track to be able to share the first data from our phase III clinical trials in the second quarter. 

“We believe that iclaprim, if approved, can be an important option for patients hospitalised with ABSSSI who also have kidney disease with or without diabetes.”

It is estimated that up to 26% of the 3.6mln ABSSSI patients hospitalised annually in the US have kidney disease.

The stock rose 6% to 26.5p. Northland Capital reckons a “positive readout” from REVIVE-1 could “would likely trigger a significant rerating of the shares”.  

Analyst Vadim Alexandre reckons the Motif is worth 90p.


Quick facts: Motif Bio PLC

Price: 0.0576 GBX

Market: AIM
Market Cap: £279.56 k

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Enthusiasm of Belvoir Group franchisees during crisis has been incredible...

Dorian Gonsalves, chief executive of Belvoir Group PLC, says the company’s franchisees will be ready to go straight out and start letting again as soon as the lockdown is lifted. Belvoir is actively transacting business on all sides except estate agency, where transactions have all but...

4 hours, 59 minutes ago

2 min read